ArticleClinical epigenetics2015
Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer.
Article in Clinical epigenetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 43 citations in OpenAlex.
- Article
- An integrative analysis combining bioinformatics, network pharmacology and experimental methods identified key genes of EGCG targets in Nasopharyngeal Carcinoma.Discover oncology · 2025Article
- Advances in colorectal cancer screening and detection: a narrative review on biomarkers, imaging and preventive strategies.Journal of the Egyptian National Cancer Institute · 2025Review
- STForte: tissue context-specific encoding and consistency-aware spatial imputation for spatially resolved transcriptomics.Briefings in bioinformatics · 2025Article
- Crosstalk between P2Y receptors and cyclooxygenase activity in inflammation and tissue repair.Purinergic signalling · 2024Review
- Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments.Pharmaceutics · 2024Review
- Colorectal Cancer Chemoprevention: A Dream Coming True?International journal of molecular sciences · 2023Review
- PTGES Expression Is Associated with Metabolic and Immune Reprogramming in Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2023Article
- Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma.Analytical cellular pathology (Amsterdam) · 2023Article
- Role and mechanism of DNA methylation and its inhibitors in hepatic fibrosis.Frontiers in genetics · 2023Review
- Network pharmacology-based strategy for predicting therapy targets of Sanqi and Huangjing in diabetes mellitus.World journal of clinical cases · 2022Article
- Hypoxia-hindered methylation of PTGIS in endometrial stromal cells accelerates endometriosis progression by inducing CD16Experimental & molecular medicine · 2022Article
- Immunological significance of alternative splicing prognostic signatures for bladder cancer.Heliyon · 2022Article
- Anti-neoplastic characteristics and potential targets of calycosin against bisphenol A-related osteosarcoma: bioinformatics analysis.Bioengineered · 2021Article
- Alternative activation of macrophages by prostacyclin synthase ameliorates alcohol induced liver injury.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- High expression of regulator of G-protein signalling 1 is associated with the poor differentiation and prognosis of gastric cancer.Oncology letters · 2021Article
- Cyclooxygenase 2 Effector Genes as Potential Inflammation-Related Biomarkers for Colorectal Cancer Circulating Tumor Cells Detection by Liquid Biopsy.Frontiers in pharmacology · 2021Article
- Epigenetics of Hepatic Insulin Resistance.Frontiers in endocrinology · 2021Review
- Exploration of Lipid Metabolism in Gastric Cancer: A Novel Prognostic Genes Expression Profile.Frontiers in oncology · 2021Article
- Targeting Nuclear Factor-Kappa B Signaling Pathway by Curcumin: Implications for the Treatment of Multiple Sclerosis.Advances in experimental medicine and biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMisregulation of the PTGS (prostaglandin endoperoxide synthase, also known as cyclooxygenase or COX) pathway may lead to the accumulation of pro-inflammatory signals, which constitutes a hallmark of cancer. To get insight into the role of this signaling pathway in colorectal cancer (CRC), we have characterized the transcriptional and epigenetic landscapes of the PTGS pathway genes in normal and cancer cells.
resultsData from four independent series of CRC patients (502 tumors including adenomas and carcinomas and 222 adjacent normal tissues) and two series of colon mucosae from 69 healthy donors have been included in the study. Gene expression was analyzed by real-time PCR and Affymetrix U219 arrays. DNA methylation was analyzed by bisulfite sequencing, dissociation curves, and HumanMethylation450K arrays. Most CRC patients show selective transcriptional deregulation of the enzymes involved in the synthesis of prostanoids and their receptors in both tumor and its adjacent mucosa. DNA methylation alterations exclusively affect the tumor tissue (both adenomas and carcinomas), redirecting the transcriptional deregulation to activation of prostaglandin E2 (PGE2) function and blockade of other biologically active prostaglandins. In particular, PTGIS, PTGER3, PTGFR, and AKR1B1 were hypermethylated in more than 40 % of all analyzed tumors.
conclusionsThe transcriptional and epigenetic profiling of the PTGS pathway provides important clues on the biology of the tumor and its microenvironment. This analysis renders candidate markers with potential clinical applicability in risk assessment and early diagnosis and for the design of new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.